Emicizumab Prophylaxis in Hemophilia A with Inhibitors

Inhibitors develop in many patients with hemophilia who receive recombinant factor VIII. Prophylaxis with emicizumab, an antibody that functionally replaces factor VIII in the clotting pathway, reduced the rate of bleeding events among patients with hemophilia with inhibitors.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2017-08, Vol.377 (9), p.809-818
Hauptverfasser:	Oldenburg, Johannes, Mahlangu, Johnny N, Kim, Benjamin, Schmitt, Christophe, Callaghan, Michael U, Young, Guy, Santagostino, Elena, Kruse-Jarres, Rebecca, Negrier, Claude, Kessler, Craig, Valente, Nancy, Asikanius, Elina, Levy, Gallia G, Windyga, Jerzy, Shima, Midori
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Antibodies Antibodies, Bispecific - adverse effects Antibodies, Bispecific - pharmacokinetics Antibodies, Bispecific - therapeutic use Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - pharmacokinetics Antibodies, Monoclonal, Humanized - therapeutic use Bleeding Blood Coagulation Factors - adverse effects Blood Coagulation Factors - therapeutic use Child Coagulation factors Drug dosages Drug Therapy, Combination Factor VIIa - therapeutic use Factor VIII - immunology Factor VIII - therapeutic use Factor VIII deficiency Hematology Hemophilia Hemophilia A - drug therapy Hemophilia A - immunology Hemorrhage Hemorrhage - prevention & control Humans Injections, Subcutaneous Isoantibodies - blood Male Medicine Middle Aged Monoclonal antibodies Prophylaxis Prothrombin Recombinant Proteins - therapeutic use Recovery of function Thrombosis Thrombosis - chemically induced Thrombotic microangiopathy Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Inhibitors develop in many patients with hemophilia who receive recombinant factor VIII. Prophylaxis with emicizumab, an antibody that functionally replaces factor VIII in the clotting pathway, reduced the rate of bleeding events among patients with hemophilia with inhibitors.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa1703068